MARKET

VTVT

VTVT

VTV THERAPEUTICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.440
+0.090
+3.83%
Pre Market: 2.400 -0.04 -1.64% 07:44 03/04 EST
OPEN
2.630
PREV CLOSE
2.350
HIGH
2.630
LOW
2.430
VOLUME
1.54K
TURNOVER
--
52 WEEK HIGH
4.750
52 WEEK LOW
1.440
MARKET CAP
196.77M
P/E (TTM)
-12.6951
1D
5D
1M
3M
1Y
5Y
Glucokinase Market Report Share 2021, Analysis Size by Regions, Growth Factors, Top Revenues, Different Countries with Development Status, Forecast to 2027
Mar 04, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Glucokinase Market” 2021 report...
The Express Wire · 5h ago
Thinking about buying stock in Greenlane Holdings, vTv Therapeutics, Evolus Inc, Applied DNA Sciences, or Mogo Inc?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNLN, VTVT, EOLS, APDN, and MOGO.
PR Newswire - PRF · 22h ago
How Much Are vTv Therapeutics Inc. (NASDAQ:VTVT) Insiders Spending On Buying Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Simply Wall St. · 1d ago
Making A List Of Penny Stocks? 5 Active Names To Watch This Week
Penny Stocks · 1d ago
3 Penny Stocks Turning Heads Before March But Are They A Buy Now?
Feb 26, 2021 (Penny Stocks via COMTEX) -- As February comes to a close, we are seeing more volatility than ever among both blue chip and penny stocks. To...
Penny Stocks · 5d ago
Dementia with Diabetes - Pipeline Insight, 2020
Feb 26, 2021 (Heraldkeepers) -- DelveInsight's, "Dementia with Diabetes - Pipeline Insight, 2020," report provides comprehensive insights about 5+ companies...
Heraldkeepers · 6d ago
Thinking about buying stock in GameStop, AMC Entertainment, Dynatronics Corp, Selecta Biosciences, or vTv Therapeutics?
PR Newswire - PRF · 6d ago
vTv Therapeutics (VTVT) Receives a Buy from Northland Securities
In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on vTv Therapeutics (VTVT), with a price target of $7.50. The
SmarterAnalyst · 02/25 12:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTVT. Analyze the recent business situations of VTV THERAPEUTICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VTVT stock price target is 6.75 with a high estimate of 7.50 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 2.70M
% Owned: 3.35%
Shares Outstanding: 80.64M
TypeInstitutionsShares
Increased
14
115.87K
New
23
-1.16M
Decreased
7
508.19K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Executive Director
Robin Abrams
President/Chief Executive Officer
Stephen Holcombe
Chief Financial Officer/Executive Vice President
Rudy Howard
Director
Hersh Kozlov
Director
Richard Nelson
Independent Director
John Fry
Independent Director
Noel Spiegel
Independent Director
Howard Weiner
No Data
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Webull offers kinds of vTv Therapeutics Inc stock information, including NASDAQ:VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.